桂参止痛合剂治疗中重度晚期癌症疼痛的临床评价

CLINICAL EVALUATION OF THE ANALGESIC EFFECT OF COMDRUGCIDE ON CANCER PAIN

目的 :观察桂参止痛合剂 (康赛德 )对晚期癌症伴中重度疼痛患者的镇痛效果与不良反应。方法 :6 9例癌痛患者随机分为两组 ,试验组 (36例 )应用桂参止痛合剂 5 0～ 15 0ml,每 8小时 1次 ,对照组 (33例 )路盖克片 1～ 2片 ,每 6小时 1次。两组均连用 7天。评价指标为疼痛强度 ,疼痛缓解率 ,生活质量、不良反应。结果 :桂参止痛合剂总的疼痛缓解率为 80 .6 % ,对中、重度疼痛的缓解率分别为 92 .6 %、5 5 .6 %。与对照组相比 ,止痛效果无显著性差异 ,但生活质量改善明显为优 ,不良反应低 ,患者接受程度好。结论 :桂参止痛合剂是治疗中度癌痛较好的药物。

Objective: To evaluate the analgesic effect of Comdrugcide in the treatment of cancer pain.Methods: 69 cancer patients with moderate and severe pain were divided randomly to receive Comdrugcide 50～150ml q8h(n=36) or Galake 1～2# q6h(n=33) for seven days.Results:The total remission rate of Comdrugcide on cancer pain was 83.3% and those for moderate and severe pain were 92.6% and 55.6%, respectively,similar to those of Galake. It had better quality of life, few and slighter side-effects.Conclusion: Comdrugcide is an effective and safe agent for treatment of moderate cancer pain.